Natera said it is preparing to accelerate prospective study readouts for its Signatera MRD test, with a view toward demonstrating clinical utility across tumor types. The company highlighted SIGNAL-ER 101, an interventional study designed to determine whether MRD-guided escalation to CDK4/6 inhibitors improves outcomes in HR-positive, HER2-negative breast cancer after surgery. Natera’s plan centers on interventional “SIGNAL portfolio” studies intended to connect MRD detection with treatment decision pathways rather than only prognostic stratification. The CEO also emphasized that Natera funded practice-changing studies for each histology believed to have meaningful business and clinical impact. Separately, management reported Q2 revenue growth of 38% year over year, driven by increased test volume and average selling price improvements—supporting the operational capacity to run multiple prospective studies.